 Michael Szarek
Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 33 | 2023 | 257 | 6.290 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 37 | 2023 | 387 | 5.050 |
Why?
| | Anticholesteremic Agents | 20 | 2023 | 130 | 4.200 |
Why?
| | Antibodies, Monoclonal, Humanized | 32 | 2023 | 667 | 3.500 |
Why?
| | Cholesterol, LDL | 33 | 2023 | 316 | 2.410 |
Why?
| | Peripheral Arterial Disease | 11 | 2022 | 377 | 1.900 |
Why?
| | Heptanoic Acids | 20 | 2014 | 62 | 1.900 |
Why?
| | Stroke | 14 | 2022 | 1047 | 1.800 |
Why?
| | Pyrroles | 20 | 2014 | 191 | 1.760 |
Why?
| | Ischemic Attack, Transient | 4 | 2020 | 62 | 1.550 |
Why?
| | Myocardial Infarction | 15 | 2022 | 968 | 1.500 |
Why?
| | Lipoprotein(a) | 10 | 2023 | 49 | 1.330 |
Why?
| | Glycosides | 4 | 2023 | 34 | 1.230 |
Why?
| | Proprotein Convertase 9 | 13 | 2023 | 60 | 1.190 |
Why?
| | Dyslipidemias | 5 | 2020 | 162 | 1.110 |
Why?
| | Angina, Unstable | 7 | 2019 | 74 | 1.110 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2022 | 402 | 1.040 |
Why?
| | Brain Ischemia | 7 | 2022 | 310 | 1.020 |
Why?
| | Treatment Outcome | 43 | 2023 | 9341 | 1.000 |
Why?
| | Rivaroxaban | 10 | 2022 | 208 | 0.980 |
Why?
| | Diabetes Mellitus, Type 2 | 9 | 2023 | 2173 | 0.860 |
Why?
| | Antibodies, Monoclonal | 5 | 2023 | 1284 | 0.860 |
Why?
| | Double-Blind Method | 23 | 2023 | 1687 | 0.760 |
Why?
| | Heart Failure | 6 | 2023 | 1969 | 0.760 |
Why?
| | Hypercholesterolemia | 7 | 2020 | 93 | 0.720 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 174 | 0.670 |
Why?
| | Lower Extremity | 7 | 2022 | 335 | 0.640 |
Why?
| | Cardiovascular Diseases | 14 | 2022 | 1796 | 0.640 |
Why?
| | Patient Admission | 1 | 2019 | 176 | 0.630 |
Why?
| | Simvastatin | 4 | 2010 | 65 | 0.600 |
Why?
| | Humans | 92 | 2023 | 118931 | 0.590 |
Why?
| | Drug Therapy, Combination | 11 | 2022 | 965 | 0.590 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 334 | 0.590 |
Why?
| | Aged | 48 | 2022 | 19644 | 0.560 |
Why?
| | Venous Thromboembolism | 3 | 2023 | 234 | 0.490 |
Why?
| | Patient Readmission | 1 | 2019 | 634 | 0.480 |
Why?
| | Global Health | 3 | 2021 | 310 | 0.480 |
Why?
| | Aspirin | 8 | 2022 | 334 | 0.450 |
Why?
| | Life Change Events | 1 | 2014 | 134 | 0.450 |
Why?
| | Middle Aged | 43 | 2023 | 27607 | 0.450 |
Why?
| | Secondary Prevention | 5 | 2019 | 227 | 0.430 |
Why?
| | Male | 56 | 2023 | 57784 | 0.420 |
Why?
| | Career Choice | 1 | 2014 | 192 | 0.420 |
Why?
| | Markov Chains | 2 | 2010 | 118 | 0.410 |
Why?
| | Ischemia | 4 | 2022 | 374 | 0.410 |
Why?
| | Female | 55 | 2023 | 61547 | 0.400 |
Why?
| | Factor Xa Inhibitors | 5 | 2022 | 138 | 0.370 |
Why?
| | Cholesterol | 3 | 2022 | 373 | 0.370 |
Why?
| | Serine Proteinase Inhibitors | 2 | 2020 | 35 | 0.360 |
Why?
| | Students, Medical | 1 | 2014 | 311 | 0.350 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2010 | 156 | 0.340 |
Why?
| | Apolipoproteins B | 6 | 2022 | 44 | 0.340 |
Why?
| | Coronary Disease | 5 | 2009 | 356 | 0.330 |
Why?
| | Vascular Surgical Procedures | 2 | 2021 | 262 | 0.330 |
Why?
| | Follow-Up Studies | 8 | 2023 | 4596 | 0.320 |
Why?
| | Endovascular Procedures | 2 | 2022 | 276 | 0.320 |
Why?
| | Risk Factors | 16 | 2022 | 8998 | 0.300 |
Why?
| | Models, Statistical | 1 | 2010 | 636 | 0.280 |
Why?
| | Cholesterol, HDL | 4 | 2019 | 198 | 0.280 |
Why?
| | Proportional Hazards Models | 9 | 2019 | 1125 | 0.280 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2023 | 589 | 0.270 |
Why?
| | Survival Analysis | 1 | 2008 | 1266 | 0.250 |
Why?
| | Anticoagulants | 4 | 2023 | 559 | 0.250 |
Why?
| | HIV-1 | 1 | 2010 | 776 | 0.250 |
Why?
| | Rosuvastatin Calcium | 2 | 2022 | 19 | 0.250 |
Why?
| | Internship and Residency | 1 | 2014 | 1001 | 0.240 |
Why?
| | Primary Health Care | 1 | 2014 | 1556 | 0.240 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 79 | 0.220 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 44 | 0.220 |
Why?
| | Hyperlipidemias | 1 | 2003 | 128 | 0.220 |
Why?
| | Hospitalization | 6 | 2023 | 1785 | 0.220 |
Why?
| | Risk Assessment | 6 | 2023 | 3055 | 0.200 |
Why?
| | Muscles | 1 | 2022 | 332 | 0.190 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 208 | 0.190 |
Why?
| | Phenylurea Compounds | 1 | 2021 | 85 | 0.190 |
Why?
| | Cataract | 1 | 2023 | 194 | 0.190 |
Why?
| | Quinolines | 1 | 2021 | 128 | 0.180 |
Why?
| | Time Factors | 7 | 2020 | 6409 | 0.180 |
Why?
| | Renal Insufficiency | 1 | 2021 | 150 | 0.170 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 224 | 0.170 |
Why?
| | Kidney Diseases | 1 | 2023 | 439 | 0.170 |
Why?
| | Thrombosis | 1 | 2022 | 309 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2022 | 345 | 0.160 |
Why?
| | Lipids | 4 | 2010 | 607 | 0.160 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 143 | 0.160 |
Why?
| | Hemorrhage | 4 | 2023 | 623 | 0.160 |
Why?
| | Venous Thrombosis | 1 | 2020 | 147 | 0.160 |
Why?
| | Liver X Receptors | 1 | 2018 | 30 | 0.160 |
Why?
| | Coronary Artery Bypass | 1 | 2019 | 209 | 0.160 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 338 | 0.160 |
Why?
| | Apolipoproteins E | 1 | 2018 | 90 | 0.150 |
Why?
| | Biomarkers | 6 | 2020 | 3588 | 0.150 |
Why?
| | Diabetes Complications | 1 | 2019 | 218 | 0.150 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 554 | 0.150 |
Why?
| | Prospective Studies | 8 | 2022 | 6471 | 0.150 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2018 | 57 | 0.150 |
Why?
| | Neoplasms, Experimental | 1 | 2018 | 158 | 0.150 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2023 | 3360 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2021 | 1944 | 0.150 |
Why?
| | Immunotherapy, Adoptive | 1 | 2018 | 191 | 0.140 |
Why?
| | HIV Infections | 1 | 2010 | 2459 | 0.140 |
Why?
| | Myocardial Ischemia | 3 | 2007 | 251 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 900 | 0.130 |
Why?
| | Phospholipids | 2 | 2009 | 208 | 0.130 |
Why?
| | Hospital Mortality | 1 | 2019 | 814 | 0.130 |
Why?
| | Killer Cells, Natural | 1 | 2018 | 381 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 628 | 0.130 |
Why?
| | Proprotein Convertases | 1 | 2014 | 14 | 0.130 |
Why?
| | Receptors, Interleukin-3 | 1 | 2014 | 7 | 0.120 |
Why?
| | Antigens, Neoplasm | 2 | 2006 | 227 | 0.120 |
Why?
| | Adult | 14 | 2023 | 31508 | 0.120 |
Why?
| | Disease-Free Survival | 2 | 2018 | 648 | 0.120 |
Why?
| | Neoplasms | 2 | 2023 | 2177 | 0.120 |
Why?
| | Skin Neoplasms | 2 | 2014 | 762 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 647 | 0.110 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 969 | 0.110 |
Why?
| | Hematologic Neoplasms | 1 | 2014 | 133 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2015 | 278 | 0.110 |
Why?
| | Developing Countries | 1 | 2014 | 255 | 0.110 |
Why?
| | Immunity, Innate | 1 | 2018 | 745 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 941 | 0.100 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 532 | 0.100 |
Why?
| | Urban Population | 1 | 2014 | 409 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 652 | 0.100 |
Why?
| | Heparin | 2 | 2023 | 230 | 0.100 |
Why?
| | Sodium-Glucose Transporter 1 | 2 | 2020 | 12 | 0.100 |
Why?
| | Dendritic Cells | 1 | 2014 | 442 | 0.100 |
Why?
| | Norway | 1 | 2010 | 35 | 0.100 |
Why?
| | Bottle Feeding | 1 | 2010 | 22 | 0.100 |
Why?
| | Denmark | 1 | 2010 | 41 | 0.100 |
Why?
| | Netherlands | 1 | 2010 | 62 | 0.100 |
Why?
| | Sweden | 1 | 2010 | 63 | 0.090 |
Why?
| | Finland | 1 | 2010 | 71 | 0.090 |
Why?
| | Serum Amyloid A Protein | 2 | 2007 | 28 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 1974 | 0.090 |
Why?
| | Likelihood Functions | 1 | 2010 | 136 | 0.090 |
Why?
| | Arteries | 2 | 2022 | 250 | 0.090 |
Why?
| | Aged, 80 and over | 7 | 2020 | 6555 | 0.090 |
Why?
| | Risk | 6 | 2008 | 853 | 0.090 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 72 | 0.090 |
Why?
| | Probability | 1 | 2010 | 305 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 403 | 0.090 |
Why?
| | Biomarkers, Tumor | 2 | 2006 | 1059 | 0.090 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2009 | 11 | 0.090 |
Why?
| | Melanoma | 2 | 2006 | 664 | 0.090 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1440 | 0.080 |
Why?
| | United States Government Agencies | 1 | 2008 | 6 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2019 | 2235 | 0.080 |
Why?
| | Inflammation | 4 | 2023 | 2566 | 0.080 |
Why?
| | C-Reactive Protein | 2 | 2007 | 360 | 0.080 |
Why?
| | Biometry | 1 | 2008 | 65 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2021 | 2849 | 0.080 |
Why?
| | United States | 3 | 2019 | 12541 | 0.080 |
Why?
| | Counseling | 1 | 2010 | 353 | 0.080 |
Why?
| | Decision Making | 1 | 2014 | 807 | 0.070 |
Why?
| | Incidence | 3 | 2022 | 2424 | 0.070 |
Why?
| | Recurrence | 4 | 2019 | 975 | 0.070 |
Why?
| | Breast Feeding | 1 | 2010 | 386 | 0.070 |
Why?
| | Fibrinolytic Agents | 2 | 2022 | 238 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2009 | 576 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 336 | 0.070 |
Why?
| | Albuminuria | 2 | 2023 | 195 | 0.070 |
Why?
| | Acute Disease | 3 | 2021 | 940 | 0.070 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1032 | 0.070 |
Why?
| | Cancer Vaccines | 1 | 2006 | 139 | 0.060 |
Why?
| | Lipoproteins, HDL | 1 | 2005 | 82 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2004 | 90 | 0.060 |
Why?
| | CD40 Ligand | 1 | 2004 | 46 | 0.060 |
Why?
| | Medication Adherence | 1 | 2009 | 555 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2004 | 138 | 0.060 |
Why?
| | Subtilisins | 1 | 2023 | 10 | 0.060 |
Why?
| | Thromboplastin | 1 | 2023 | 68 | 0.060 |
Why?
| | Ezetimibe | 1 | 2022 | 23 | 0.060 |
Why?
| | Creatine Kinase | 1 | 2022 | 75 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 8 | 0.050 |
Why?
| | Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2021 | 4 | 0.050 |
Why?
| | Pharmacogenomic Testing | 1 | 2022 | 54 | 0.050 |
Why?
| | Creatine | 1 | 2021 | 56 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2005 | 394 | 0.050 |
Why?
| | Goals | 1 | 2022 | 167 | 0.050 |
Why?
| | Inflammation Mediators | 1 | 2004 | 502 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2022 | 209 | 0.050 |
Why?
| | Algorithms | 1 | 2008 | 1541 | 0.050 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 136 | 0.050 |
Why?
| | Stroke Volume | 1 | 2023 | 512 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 237 | 0.050 |
Why?
| | Mycoses | 1 | 2020 | 69 | 0.050 |
Why?
| | Ventricular Function, Left | 1 | 2023 | 468 | 0.050 |
Why?
| | Mice, Nude | 1 | 2021 | 663 | 0.040 |
Why?
| | Odds Ratio | 3 | 2009 | 995 | 0.040 |
Why?
| | Antigens, CD | 1 | 2022 | 460 | 0.040 |
Why?
| | Diarrhea | 1 | 2020 | 181 | 0.040 |
Why?
| | Propensity Score | 1 | 2021 | 242 | 0.040 |
Why?
| | Placebo Effect | 1 | 2019 | 52 | 0.040 |
Why?
| | Age Factors | 1 | 2007 | 2995 | 0.040 |
Why?
| | Hypotension | 1 | 2020 | 120 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2019 | 138 | 0.040 |
Why?
| | Transplantation, Haploidentical | 1 | 2018 | 7 | 0.040 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 168 | 0.040 |
Why?
| | American Heart Association | 1 | 2019 | 270 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2017 | 1243 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2021 | 551 | 0.040 |
Why?
| | Cell Count | 1 | 2018 | 315 | 0.040 |
Why?
| | Erythrocytes | 1 | 2022 | 641 | 0.040 |
Why?
| | Mice, SCID | 1 | 2018 | 333 | 0.040 |
Why?
| | Infant | 1 | 2010 | 8293 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 5116 | 0.040 |
Why?
| | Muscular Diseases | 2 | 2008 | 107 | 0.040 |
Why?
| | Morbidity | 1 | 2017 | 296 | 0.030 |
Why?
| | Vascular Diseases | 1 | 2019 | 241 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 574 | 0.030 |
Why?
| | Apolipoproteins | 2 | 2007 | 39 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2022 | 1055 | 0.030 |
Why?
| | Immunoglobulin M | 2 | 2009 | 253 | 0.030 |
Why?
| | Tissue Donors | 1 | 2018 | 336 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1323 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 740 | 0.030 |
Why?
| | Cytoplasm | 2 | 2006 | 269 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 380 | 0.030 |
Why?
| | Fluorobenzenes | 1 | 2014 | 13 | 0.030 |
Why?
| | Interleukin-3 | 1 | 2014 | 25 | 0.030 |
Why?
| | Syndrome | 2 | 2007 | 344 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 2015 | 118 | 0.030 |
Why?
| | Diphtheria Toxin | 1 | 2014 | 63 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2275 | 0.030 |
Why?
| | Serine Endopeptidases | 1 | 2014 | 105 | 0.030 |
Why?
| | Oxidation-Reduction | 2 | 2009 | 940 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2020 | 709 | 0.030 |
Why?
| | Mice | 2 | 2021 | 15520 | 0.030 |
Why?
| | Child, Preschool | 2 | 2005 | 9491 | 0.030 |
Why?
| | Prognosis | 3 | 2005 | 3440 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 2015 | 231 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 2007 | 1473 | 0.030 |
Why?
| | Immunoglobulin G | 2 | 2009 | 788 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 702 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2006 | 1221 | 0.030 |
Why?
| | Interleukin-6 | 2 | 2007 | 688 | 0.030 |
Why?
| | Adolescent | 3 | 2006 | 18480 | 0.030 |
Why?
| | Pyrimidines | 1 | 2014 | 382 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 2680 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 356 | 0.020 |
Why?
| | Sulfonamides | 1 | 2014 | 445 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 1867 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 3457 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1418 | 0.020 |
Why?
| | Autoantibodies | 2 | 2009 | 1335 | 0.020 |
Why?
| | Ireland | 1 | 2008 | 25 | 0.020 |
Why?
| | Apolipoprotein A-I | 1 | 2008 | 26 | 0.020 |
Why?
| | Europe | 1 | 2009 | 356 | 0.020 |
Why?
| | Thromboembolism | 1 | 2009 | 99 | 0.020 |
Why?
| | Lipoproteins | 1 | 2009 | 162 | 0.020 |
Why?
| | Animals | 2 | 2021 | 33381 | 0.020 |
Why?
| | United Kingdom | 1 | 2008 | 236 | 0.020 |
Why?
| | Child | 2 | 2005 | 19128 | 0.020 |
Why?
| | Drug Prescriptions | 1 | 2009 | 248 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2673 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 187 | 0.020 |
Why?
| | Cerebral Infarction | 1 | 2006 | 45 | 0.020 |
Why?
| | ROC Curve | 1 | 2007 | 473 | 0.020 |
Why?
| | Hematuria | 1 | 2005 | 11 | 0.020 |
Why?
| | Immunotherapy, Active | 1 | 2005 | 9 | 0.020 |
Why?
| | Triglycerides | 1 | 2008 | 519 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 2006 | 100 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2005 | 95 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2005 | 152 | 0.020 |
Why?
| | Apolipoprotein B-100 | 1 | 2004 | 8 | 0.020 |
Why?
| | Drug Utilization | 1 | 2005 | 169 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 736 | 0.020 |
Why?
| | Arteriosclerosis | 1 | 2004 | 88 | 0.020 |
Why?
| | Angina Pectoris | 1 | 2004 | 63 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2005 | 136 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 827 | 0.010 |
Why?
| | Solubility | 1 | 2004 | 235 | 0.010 |
Why?
| | Troponin | 1 | 2003 | 47 | 0.010 |
Why?
| | Databases, Factual | 1 | 2008 | 1231 | 0.010 |
Why?
| | Research Design | 1 | 2009 | 969 | 0.010 |
Why?
| | Heart Arrest | 1 | 2004 | 291 | 0.010 |
Why?
| | Pain | 1 | 2005 | 735 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2007 | 12972 | 0.010 |
Why?
| | Disease Progression | 1 | 2005 | 2490 | 0.010 |
Why?
| | Brain | 1 | 2007 | 2489 | 0.010 |
Why?
|
|
Szarek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|